ANI Pharmaceuticals
在场
是其中之一......
ANI Pharmaceuticals 是一家在股票代码 ANIP (US) 下上市的公司。
他们在：
涉及ANI Pharmaceuticals的并购和融资。
- ANI Pharmaceuticals 已收购 Alimera Sciences (公布2024九月16号).
- ANI Pharmaceuticals has announced the acquisition of Alimera Sciences (公布2024六月26号).
高管
查看带有其 31 名主要高管的组织结构图
ANI Pharmaceuticals 搜索最多的简介
- Nikhil Lalwani, Director, President and Chief Executive Officer
- Antonio Pera, Director
- Thomas Haughey, Director
创建提醒
跟踪 ANI Pharmaceuticals 的高管变动
生物技术
ANI Pharmaceuticals 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
ANI Pharmaceuticals 的最新新闻稿
- ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
- ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
- ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
- ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
- ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
- ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
- ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
- ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
- ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
- ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
- View more press releases Close
通过电子邮件
